Cardiometabolic and Lipids Strategies for Endocrinologists-Cardiovascular Disease and Diabetes-Assessing Risks and Prioritizing Therapies

Video Transcription

Video Summary

In this video, Dr. Peter Rieben discusses cardiovascular disease and diabetes, focusing on assessing risks and prioritizing therapies. He discusses the benefits and limitations of various diabetes medications and their effects on cardiovascular disease. He specifically mentions the benefits of metformin, thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. He suggests that glucose variability and blood pressure variability may also be important factors to consider in managing diabetes and cardiovascular disease risk. Dr. Rieben suggests that a combination of glucose lowering, hypoglycemia reduction, and glucose variability reduction should be considered when managing diabetes patients. He also discusses the potential benefits of combining GLP1 receptor agonists and SGLT2 inhibitors. Dr. Rieben briefly touches on the use of continuous glucose monitoring and its potential benefits in managing diabetes patients. He concludes by emphasizing the importance of comprehensive management of all risk factors and the need to personalize treatment approaches for each patient.

Keywords

cardiovascular disease

diabetes

assessing risks

diabetes medications

metformin

GLP1 receptor agonists

SGLT2 inhibitors

glucose variability

personalized treatment